血管生成抑制剂研究的进展

摘要/Abstract

摘要： 血管生成是实体肿瘤细胞的生长和转移的必要条件, 血管生成能够为肿瘤细胞提供更多的营养物质和氧气。阻止肿瘤血管网的形成能够使肿瘤变小, 能够阻止肿瘤的转移。由于抗血管生成药物具有毒性低、不易产生获得性耐药的特点。因此, 通过抑制血管生成来抑制肿瘤生长成为目前肿瘤治疗的策略之一。

关键词: 肿瘤, 血管生成, 基质金属蛋白酶, 抑制剂

Abstract: Angiogenesis is essential for cancer growth and metastasis, which is a crucial process as it furnishes tumor cell with enough nutrients and oxygen.Tumor size can be reduced and metastasis of tumor be blocked if the formation of new blood vessel networks is prevented.As the features of angiogenesis inhibitors are of low toxicity and have less acquired resistance, it comes to a new strategy to suppress tumor growth by restraining angiogenesis.

Key words: tumor, angiogenesis, MMPs, inhibitor

中图分类号:

R730.5

黄维, 关勇彪. 血管生成抑制剂研究的进展[J]. 中国临床药理学与治疗学, 2007, 12(4): 376-380.

HUANG Wei, GUAN Yong-biao. Advances in studies of angiogenesis inhibitor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(4): 376-380.

参考文献

1 Hanahan D, Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell, 1996;86: 353-364.
2 Ferrara N,Gerber HP, LeCouter J.The biology of VEGF and its receptors[J].NatMed, 2003;9:669-676.
3 Muhammad WS.Anti-Angiogenesis Therapy in Pancreatic Carcinoma[J].JOP J Pancreas (Online), 2006;7:163-173.
4 Schueneman AJ, Himmelfarb E, GenG L, et al.SU11248 maintenance therapy prevents tumour regrowth after fractionated irradiation of murine tumour models[J].Cancer Res, 2003;63: 4009-4016.
5 Motzer RJ, Rini BI, Michaelson MD, et al.SU011248, a novel tyrosine kinase inhibitor, shows antitumour activity in secondline therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial[J].Proc Am Soc Clin Oncol, 2004; 23:381.
6 Morgan B, Thomas AL, Drevs J, et al.Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787 ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colourectal cancer and liver metastases: results from two phase I studies[J].J Clin Oncol, 2003;21: 3955-3964.
7 Steward WP, Thomas A, Morgan B, et al.Expanded phase I II study of PTK787 ZK 222584 (PTK ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colourectal[J].Proc Am Soc Clin Oncol, 2004;23:259.
8 George D, Michaelson, Oh WK, et al.Phase I study of PTK787 ZK 222584 (PTK ZK)in metastatic renal cell carcinoma[J]. Proc Am Soc Clin Oncol, 2003;22:385.
9 Willett CG, Boucher Y, Di Tomaso E, et al.Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer[J].Nat Med, 2004;10:145-147.
10 Posey JA, Ng TC, Yang B, et al.A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colourectal carcinoma[J].Clin Cancer Res, 2003;9:1323-1332.
11 Jimenoa J, Lopez-Martyna JA, Ruiz-Casadoa A, et al.Progress in the clinical development of new marine derived anticancer compounds[J].Anti-Cancer Drugs, 2004;15:321-329.
12 Dupont J, Camastra D, GordonMS, et al.Phase I study of VEGF TRAP in patients with solid tumours and lymphoma[J].Proc Am Soc Clin Oncol, 2003;22:194.
13 Pruthi RS, Derksen JE,Moore D.A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy[J]. BJU Int, 2004;93:275-278.
14 Moore MJ, Hamm J, Dancey J, et al.Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas:a phase III trial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol, 2003;21:3296-3302.
15 Crombet T, Osorio M, Cruz T, et al.Use of the humanised antiepidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients[J].J Clin Oncol, 2004; 22:1646-1654.
16 RansonM.Epidermal growth factor receptor tyrosine kinase inhibitors[J].Br J Cancer, 2004;90:2250-2255.
17 Faivre SJ, Chieze S, Marty M, et al.Safety profile and pharmacokinetic analysis of MEDI-522, a novel humanised monoclonal antibody that targets avb3 integrin receptor, in patients with refractory solid tumours[J].Proc Am Soc Clin Oncol, 2003;22: 208.
18 FranksME, Macpherson GR, Figg WD.Thalidomide[J].Lancet, 2004;363:1802-1811.
19 Teo SK, Stirling DI, Zeldis JB.Thalidomide as a novel therapeutic agent:new uses for an old product[J].Drug Discovery Today, 2005;10:107-114.
20 Kulke M, Bergsland E, Ryan DP, et al.A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumours[J].Proc Am Soc Clin Oncol, 2003;22:239.
21 Gordon MS,Mendelson D, GuirguisMS, et al.ABT-510, an anti-angiogenic thrombospondin-1 (TSP-1)mimetic peptide, exhibits favorable safety profile and early signals of activity in a randomised phase IB trial[J].Proc Am Soc Clin Oncol, 2003; 22:195.
22 Dutcher JP.Mammalian Target of Rapamy cin Inhibition[J].Clin Cancer Res, 2004;10:6382S-6387S.
23 Vincent L, Kermani P, YounG LM, et al.Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling[J].J Clin Invest, 2005;115:2992-3006.
24 Cooney MM, Radivoyevitch T, Dowlati A, et al.Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer[J].Clin Cancer Res, 2004;10:96-100

[1]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[2]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[3]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[4]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[5]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[6]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[7]	沈嘉庆, 刘毅. 酪氨酸激酶2抑制剂治疗斑块型银屑病机制与临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 323-330.
[8]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[9]	刘南玉, 岳红梅, 宋佩佩, 魏继芳, 魏雅倩, 谢莹莹, 王嘉琪. PDE4抑制剂作为肺纤维化的治疗靶点[J]. 中国临床药理学与治疗学, 2023, 28(3): 355-360.
[10]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[11]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[12]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[13]	刘丹, 刘明, 金良友, 潘娟, 辛昊儒, 刘梦圆, 李鑫, 郑坤, 冯晓灵. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1168-1176.
[14]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[15]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.